Tchambaz L, Schlatter C, Jakob M, Krahenbuhl A, Wolf P, Krahenbuhl S
Drug Saf. 2006; 29(6):509-22.
PMID: 16752933
DOI: 10.2165/00002018-200629060-00004.
Ralph L, Thomson A, Dobbs N, Twelves C
Br J Clin Pharmacol. 2004; 57(6):764-72.
PMID: 15151522
PMC: 1884520.
DOI: 10.1111/j.1365-2125.2004.02084.x.
Ormrod D, Holm K, Goa K, Spencer C
Drugs Aging. 1999; 15(5):389-416.
PMID: 10600046
DOI: 10.2165/00002512-199915050-00006.
Dobbs N, Twelves C
Br J Cancer. 1998; 77(7):1145-8.
PMID: 9569053
PMC: 2150122.
DOI: 10.1038/bjc.1998.190.
Coukell A, Faulds D
Drugs. 1997; 53(3):453-82.
PMID: 9074845
DOI: 10.2165/00003495-199753030-00008.
Clinical pharmacokinetics of idarubicin.
Robert J
Clin Pharmacokinet. 1993; 24(4):275-88.
PMID: 8491056
DOI: 10.2165/00003088-199324040-00002.
Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.
Camaggi C, Strocchi E, Carisi P, Martoni A, Melotti B, Pannuti F
Cancer Chemother Pharmacol. 1993; 32(4):301-9.
PMID: 8324872
DOI: 10.1007/BF00686176.
Clinical pharmacokinetics of epirubicin.
Robert J
Clin Pharmacokinet. 1994; 26(6):428-38.
PMID: 8070217
DOI: 10.2165/00003088-199426060-00002.
Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.
Dobbs N, Twelves C, Rizzi P, Warwick J, Metivier E, Williams R
Cancer Chemother Pharmacol. 1994; 34(5):405-10.
PMID: 8070007
DOI: 10.1007/BF00685565.
Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs. 1993; 45 Suppl 2:20-30.
PMID: 7693418
DOI: 10.2165/00003495-199300452-00005.
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker G, Faulds D
Drugs. 1993; 45(5):788-856.
PMID: 7686469
DOI: 10.2165/00003495-199345050-00011.
Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors.
Cuna G, Pavesi L, Preti P, Ganzina F
Invest New Drugs. 1983; 1(4):349-53.
PMID: 6590532
DOI: 10.1007/BF00177421.
A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
Martoni A, Giovannini M, Tomasi L, Camaggi C, Bellanova B, Monetti N
Cancer Chemother Pharmacol. 1984; 12(3):179-82.
PMID: 6584236
DOI: 10.1007/BF00256541.
Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.
Bouma J, Beijnen J, Bult A, Underberg W
Pharm Weekbl Sci. 1986; 8(2):109-33.
PMID: 3520474
DOI: 10.1007/BF02086146.
Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.
Eksborg S, Stendahl U, Lonroth U
Eur J Clin Pharmacol. 1986; 30(5):629-31.
PMID: 3463510
DOI: 10.1007/BF00542426.
Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.
Speth P, Linssen P, Beex L, Boezeman J, Haanen C
Cancer Chemother Pharmacol. 1986; 18(1):78-82.
PMID: 3463436
DOI: 10.1007/BF00253070.
Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients.
Camaggi C, Strocchi E, Comparsi R, TESTONI F, Angelelli B, Pannuti F
Cancer Chemother Pharmacol. 1986; 18(1):47-50.
PMID: 3463434
DOI: 10.1007/BF00253063.
A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.
Eksborg S, Andersson M, Domellof L, Lonroth U
Med Oncol Tumor Pharmacother. 1986; 3(2):105-10.
PMID: 3462442
DOI: 10.1007/BF02934562.
Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study.
Pannuti F, Camaggi C, Strocchi E, Comparsi R, Angelelli B, Pacciarini M
Cancer Chemother Pharmacol. 1986; 16(3):295-9.
PMID: 3457647
DOI: 10.1007/BF00293996.
Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
Camaggi C, Comparsi R, Strocchi E, TESTONI F, Angelelli B, Pannuti F
Cancer Chemother Pharmacol. 1988; 21(3):221-8.
PMID: 3162849
DOI: 10.1007/BF00262774.
